Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701385 | 0.81 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL5833043 | 0.78 | NOS3 (0.53) | SLC6A3SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL6699898 | 0.77 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL4965387 | 0.77 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL6625146 | 0.76 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL10697895 | 0.75 | CYP1A2 (0.50) | SLC6A2SLC6A4CYP1A2CYP2D6 | |
| SCHEMBL7795758 | 0.74 | SLC6A3 (0.38) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL5833770 | 0.74 | NOS3 (0.51) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL13088793 | 0.74 | SLC6A2 (0.60) | SLC6A3SLC6A2SLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10571109 | 0.74 | CYP1A2 (0.48) | SLC6A2SLC6A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | SLC6A3 464/4885SLC6A2 196/4885SLC6A4 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.